Men with erectile dysfunction (ED) often have low self-esteem, confidence, and sexual relationship satisfaction.
was substantially higher, ranging from 67% to 89% for men 50 to 75 years old. a Worldwide, the prevalence of ED in men aged 40 to 80 years is estimated to be 13% to 28%. 4 Although these studies employed different methodologies and cannot be compared with one another directly, they nonetheless show that the prevalence of ED is quite high. In addition, ED impacts a patient's and his partner's sexual life and is associated with depression, anxiety, and low self-esteem. 1,5
Sildenaffl citrate (Viagra ®, Pfizer Inc., NewYork, NY) is the first-in-class phosphodiesterase type 5 inhibitor for the treatment of ED and has been prescribed to more than 20 million men in more than 110 countries. 6 Accumulating evidence from numerous double-blind placebo-controlled and open-label trials suggests that sildenaffl is well tolerated and effective for the treatment of ED of diverse etiology. 7'8 Further, successful treatment of ED may be associated with improved measures of quality of life (QoL). 5 However, correlations between successful ED treatment and changes in psychosocial measures have been difficult to determine because QoL is difficult to defne and contains multiple components. Generic measures of QoL are not able to detect unique changes in men with ED, and ED-specific efficacy instruments fail to address relevant psychosocial domains such as self-esteem, confidence, and relationships.
The Self-Esteem And Relationship (SEAR) questionnaire (Appendix I available in the online version of JGIM) is a validated 14-item instrument that underwent rigorous development and validation using established psychometric principles. A psychometric evaluation of 98 men with ED and 94 age-matched controls showed discriminant validity of the SEAR for measuring self-esteem as well as relationship satisfaction and confidence.9 A 10-week, open-label study suggested that the SEAR questionnaire is responsive to effective ED treatment and is a valid instrument for detecting psychosocial gains from beneficial intervention, to The SEAR was linguistically translated and culturally adapted to assess changes from baseline to end of treatment in relationships, confidence, and In this report, we present the combined results from patients with ED from 5 different nations who were enrolled in a randomized, double-blind, placebo-controlled study of sildenafil. The objective was to verify treatment responsiveness and generalizability of the SEAR crossculturally and further establish the validity of assessing the psychosocial impact of successful treatment of ED.
PATIENTS AND METHODS

Study Design
The data from 2 randomized, parallel-group, double-blind, placebo-controlled, fiexible-dose studies of 12-week duration was combined. Patients were enrolled in 1 study in the United States and in an identical study conducted in Mexico, Brazil, Australia, and Japan. The studies were approved by appropriate local Independent Review Boards, and were conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.
Sample Size
In the SEAR responsiveness study, a mean --SD change from baseline of 4.7 :k 4.4 points was observed for the Self-Esteem subscale. 11 Using these values in a regression analysis for each study, changes from baseline for the Self-Esteem subscale were estimated to be 4.57 and 2.19 for the sildenafil and placebo groups, respectively. A sample size of 75 in each group would have 90% power with a 0.05 2-sided significance level to detect a difference in means of 2.38 with a common SD of 4.44. Responsiveness of the Sexual Relationship domain and Confidence domain were similar to that of the Self-Esteem subscale. However, the analysis revealed less treatment responsiveness for the Overall Relationship subscale. Thus, the sample size was increased to have sufficient conventional power on this secondary efficacy measure. It was estimated that a sample size of 100 in each group per trial would have 80% power with a 0.05 2-sided significance level to detect a difference in means of 1.04 with the common SD of 2.61. Assuming that 80% of randomized patients contribute to the endpoint analyses, a total sample size of 126 patients per treatment group, or 504 for the pooled analysis, was selected to be randomized according to a computer-generated randomization code that assigned subjects in a 1 : 1 ratio.
Inclusion Criteria
Male patients aged _> 18 years of age were enrolled if they had a documented clinical diagnosis of ED (confirmed by a score of _< 21 on the Sexual Health Inventory for Men). ~2 Patients eligible to receive double-blind treatment were assigned a unique randomization number at baseline, and a computer-generated randomization code assigned patients in a 1:1 ratio to treatment with either sildenai'fl or placebo.
Exclusion Criteria
Patients were excluded if they had BP<90/50 or > 170/ 110 mmHg or had significant cardiovascular disease. Patients were excluded if they were taking nitrates, nitric oxide donors, or ritonavir, or if they had taken more than 6 doses of sildenaffl before the screening visit.
Analyzed Groups
All patients who took at least 1 dose of study medication were included in the safety analysis. All patients who took at least 1 dose of study medication and who provided at least 1 postbaseline measurement were defined as the intent-to-treat population and included in the efficacy analysis.
Efficacy Measures
The primary study outcome was change from baseline to the end of treatment on the Self-Esteem subscale of the SEAR questionnaire.
Secondary measures were change scores on all other components of the SEAR and on standard efficacy measures of sexual function including the International Index of Erectile Function (IIEF) la and the percentage of sexual intercourse attempts that were successful, determined from an at-home event log of sexual activity. Patients recorded important details of the sexual experience, such as dosage, timing, hardness of erections achieved, intercourse attempts, and success on their event log worksheets as soon as possible after each occurrence of sexual activity. In addition, a standard global efficacy question (GEQ), scored on an ordinal scale from 0 (no sexual activity) to 5 (almost always/always), was asked at the end of treatment: "When you took a dose of study drug and had sexual stimulation, how often did you get an erection that allowed you to engage in satisfactory sexual intercourse?"
Safety Measures
All volunteered or observed adverse events (AEs) were systematically recorded at week 2, 4, 8, and 12 of the study using the Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART) preferred terminology. All AEs were listed by severity, body system, study medication dosage level, day of the onset, and resolution of the event.
Statistical Analysis
Change scores from baseline to week 12 were recorded for all items on the SEAR, the IIEF, and for the percentage of successful intercourse attempts. Differences in change scores from baseline were determined using an analysis of covariance model, controlling for baseline score and study, with the treatment group as the key explanatory variable. Partial Pearson's correlations (controlling for treatment and study) were obtained on changes in SEAR scores with changes in IIEF scores and changes in the percentage of intercourse attempts that were successful; SEAR scores at week 12 were correlated with the GEQ r e s p o n s e at week 12. Mean (95% confidence interval [CI]) scores are reported for within-group changes and between-group comparisons.
Treatment effect sizes were calculated for all c o m p o n e n t s of the SEAR, all domains of the IIEF, and for successful sexual intercourse attempts from the event log of sexual activity using the following calculation:
Treatment effect size Sildenafil LS m e a n change -placebo LS m e a n change Pooled baseline s t a n d a r d deviation
The difference in least squares (LS) m e a n change in SEAR scores between treatment groups was also divided by the square root of the m e a n square error (MSE) from the analysis of covariance model, which provided an estimate of the pooled SD of change scores adjusted for treatment and study. 14 The GEQ was asked only at the end of treatment. Thus, no baseline data were available. The t r e a t m e n t effect size for the GEQ was calculated using end-of-treatment data and the pooled end-of-treatment s t a n d a r d deviation. 
RESULTS
Patient Demographics
In total, 553 (US study, n =253, Brazil, Mexico, Australia, and J a p a n study, n = 3 0 0 ) patients were enrolled and randomized to receive placebo (n=274) or sildenafil (n=279) from April 2002 to February 2003. Patients in each t r e a t m e n t group were well balanced for age, race, duration of ED, and etiology of ED, with no statistically significant differences noted between t r e a t m e n t groups (Table 1) .
Change Scores on the SEAR Questionnaire
Patients randomized to the sildenafil-treated group (vs placebo) reported significant (P<.0001) and substantially higher change scores from baseline on the Self-Esteem subscale (36.6; 95% CI, 33.1 to 40.2; vs 14.1; 95% CI, 10.5 to 17,7; 
Sexual Relationship domain, C o n f d e n c e domain, Overall Relationship subscale, and Overall score. The m e a n change in the Self-Esteem subscale score for patients who received sildenafil was 22.5 (95% Ci, 17.7 to 27.4] points higher t h a n the change reported by patients who received placebo. Treatment effect sizes (determined using baseline SD or the square root of the MSE, respectively) were large for improvements in the Self-Esteem subscale (effect sizes Table 2 ).
Change Scores on the IIEF Questionnaire
Patients who received sildenafil (vs placebo) also reported significant (P< .0001) increases from baseline on the Erectile Function domain (11.0; 95% CI, 10.0 to 11.9; vs 4.8; 95% CI, 3.8 to 5.7) and on all other domains of the IIEF questionnaire ( Fig. 2) : Orgasmic Function, Sexual Desire, Intercourse Satisfaction, and Overall Satisfaction. The m e a n change in Erectile Function scores for patients receiving sildenafil was 6.2 (95% CI, 4,9 to 7.5) points higher t h a n the change reported by patients who received placebo. Treatment effect sizes were high for the EF, Intercourse Satisfaction, and Overall Satisfaction domains, and lower for the Orgasmic Function and Sexual Desire domains (Table 2) .
Change in Percentage of Successful Intercourse Attempts
The combined baseline percentage of sexual intercourse attempts that were successful was 13%. who received placebo reported a 2-fold increase (27%; 95% CI, 21% to 32%) over baseline, whereas patients who received sildenafil reported a 5-fold increase (59%; 95% CI, 54% to 64%) over baseline. This between-group change in the percentage of sexual intercourse attempts that were successful represented a difference of 32% (95% CI, 26% to 40%, P< .0001) in favor of sildenafil, and the treatment effect size was very high ( Table 2) .
Frequency of Erections for Satisfactory Intercourse
At week 12, patients who received sildenafil (vs placebo) reported higher scores on the GEQ, indicating a significantly greater [P <.0001) frequency of erections that were satisfactory for sexual intercourse (3.9; 95% CI, 3.7 to 4.1; vs 2.7; 95% CI, 2.5 to 2.9). The mean frequency for patients receiving sildenafil was 1.2 (95% CI, 0.9 to 1.5) points higher than the frequency reported by patients receiving placebo; the treatment effect size was 0.8 ( Table 2) .
Correlation of SEAR Scores with Other Instruments
Correlations between changes in SEAR components and the Erectile Function domain of the IIEF ranged from 0.52 to 0.71 (P_< .0001, Table 3 ). Correlations of changes in SEAR components were also positive and statistically significant (P< .0001) with changes in other domains of the IIEF and with changes in the percentage of successful sexual intercourse attempts. In addition, correlations in SEAR components at week 12 and the frequency of satisfactory erections were high and statistically significant (P <.0001).
Safety
In general sildenafil was well tolerated. The most frequent AEs (sildenafil vs placebo) were headache (13% vs 6%), rhinitis (5% vs 1%), dyspepsia (5% vs 2%), and flushing (8% vs 1%. Table 4 ).
COMMENT
Normal sexual function is an important component of men's physical and psychological health, and the inability to perform sexually can have a negative impact on overall health and aspects of QoL. 15 Indeed, the World Health Organization includes emotional and psychological well-being in its defnition 16 of health.
Although the IIEF is considered the gold-standard i n s t r u m e n t for measuring a patient's erectile functioning, research was needed on the psychosocial manifestations of ED and its treatment on relationships, confidence, and self-esteem. While existing disease-specific instruments have merit, they are limited psychometrically, lack an a s s e s s m e n t of treatment responsiveness, are restricted to a single s u m m a r y score, or do 17 2 0 not address pertinent psychosocial issues. -The SEAR questionnaire was developed to a s s e s s the ED-specific impact on psychosocial functioning and well-being related to sexual rela-9 1 0 tionships, confidence, and particularly self-esteem. ' The Global Study of Sexual Attitudes and Behaviors revealed that the factors associated with ED are similar across m a n y cultures. T M Thus, it is reasonable to expect crosscultural improvement in psychosocial m e a s u r e s following successful t r e a t m e n t of ED. Data generated from the SEAR questionnaire confirm that as a patient's ED improves, so too do his c o n f d e n c e , relationships, and self-esteem. The correlations of change in SEAR scores with change scores in Sexual Desire on the IIEF were lower t h a n the correlations of the other IIEF domains. It is likely that changes in psychosocial factors are more strongly related to functioning and satisfaction t h a n to changes in sexual desire. Conclusions on the SEAR questionnaire from the combined analyses across countries were maintained w h e n examined by individual country and highlight the universal improvement in psychosocial function and well-being in m e n after successful ED treatment. Results by country showed a sizable and significant effect for each SEAR component, with noticeable changes in psychosocial function and well-being after successful ED t r e a t m e n t with sildenafil. While this study focused on the aggregate findings across countries (Mexico. Brazil, Australia, J a p a n , and the United States), the results suggest that psychosocial outcomes of ED t r e a t m e n t are discernible crossculturally. The involvement of self-esteem, confidence, and relationship satisfaction in overall health and well-being suggests that the SEAR should be u s e d in conjunction with other t r e a t m e n t efficacy m e a s u r e s for a more complete a s s e s s m e n t of the psychosocial impact of ED.
CONCLUSIONS
The results of this combined analysis s u b s t a n t i a t e the psychometrically s o u n d properties of the SEAR questionnaire and the robust gains in psychosocial functioning and well-being observed crossculturally--above and beyond p l a c e b o --that a c c o m p a n y beneficial treatment with sildenafil. The data obtained from these 2 double-blind, placebo-controlled stud- 
